Sabril, Kigabeq(vigabatrin)
Kigabeq, Sabril, Vigabatrin, Vigadrone, Vigpoder (vigabatrin) is a small molecule pharmaceutical. Vigabatrin was first approved as Sabril on 2009-08-21. It is used to treat complex partial epilepsy, epilepsy, and infantile spasms in the USA. It has been approved in Europe to treat infantile spasms and partial epilepsies. The pharmaceutical is active against 4-aminobutyrate aminotransferase, mitochondrial. In addition, it is known to target vesicular inhibitory amino acid transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Sabril (generic drugs available since 2017-04-27)
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| complex partial epilepsy | EFO_1000877 | D017029 | — |
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| infantile spasms | EFO_1000643 | D013036 | G40.82 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infantile spasms | D013036 | HP_0011097 | G40.82 | — | — | 4 | 1 | 3 | 8 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | — | — | 2 | 4 | 6 |
| Seizures | D012640 | HP_0002069 | G40.4 | — | — | — | 1 | 1 | 2 |
| Intellectual disability | D008607 | EFO_0003847 | F73 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | — | F14 | 1 | 5 | 1 | — | — | 6 |
| Tuberous sclerosis | D014402 | HP_0009720 | Q85.1 | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Status epilepticus | D013226 | EFO_0008526 | G41 | — | 1 | — | — | 1 | 2 |
| Coma | D003128 | HP_0001259 | R40.2 | — | 1 | — | — | — | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | E88.819 | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | — | 1 | — | — | — | 1 |
| Tourette syndrome | D005879 | EFO_0004895 | F95.2 | 1 | 1 | — | — | — | 1 |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 1 | — | — | — | — | 1 |
| Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Complex partial epilepsy | D017029 | EFO_1000877 | — | — | — | — | — | 1 | 1 |
| Heart arrest | D006323 | EFO_0009492 | I46 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vigabatrin |
| INN | vigabatrin |
| Description | Vigabatrin is a gamma-amino acid having a gamma-vinyl GABA structure. It is an irreversible inhibitor of gamma-aminobutyric 664 acid transaminase It has a role as an anticonvulsant and an EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor. |
| Classification | Small molecule |
| Drug class | gabamimetics |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C=CC(N)CCC(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 60643-86-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL89598 |
| ChEBI ID | 63638 |
| PubChem CID | 5665 |
| DrugBank | DB01080 |
| UNII ID | GR120KRT6K (ChemIDplus, GSRS) |
Target
Agency Approved
ABAT
ABAT
Organism
Homo sapiens
Gene name
ABAT
Gene synonyms
GABAT
NCBI Gene ID
Protein name
4-aminobutyrate aminotransferase, mitochondrial
Protein synonyms
(S)-3-amino-2-methylpropionate transaminase, 4-aminobutyrate transaminase, GABA aminotransferase, GABA transaminase, GABA transferase, GABA-AT, GABA-T, Gamma-amino-N-butyrate transaminase, gamma-aminobutyrate aminotransferase, L-AIBAT
Uniprot ID
Mouse ortholog
Abat (268860)
4-aminobutyrate aminotransferase, mitochondrial (Q8BZA3)
Alternate
SLC32A1
SLC32A1
Organism
Homo sapiens
Gene name
SLC32A1
Gene synonyms
VGAT, VIAAT
NCBI Gene ID
Protein name
vesicular inhibitory amino acid transporter
Protein synonyms
GABA and glycine transporter, hVIAAT, solute carrier family 32 (GABA vesicular transporter), member 1, Solute carrier family 32 member 1, Vesicular GABA transporter
Uniprot ID
Mouse ortholog
Slc32a1 (22348)
vesicular inhibitory amino acid transporter (O35633)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,668 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,641 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use